Publications by authors named "Inge Lues"

Claim this Profile
C
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice.
Torsten Hoffmann, Jens-Ulrich Rahfeld, Mathias Schenk, Falk Ponath, Koki Makioka, Inge Lues

Int J Mol Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.
Thore Hettmann, Stephen D Gillies, Martin Kleinschmidt, Anke Piechotta, Koki Makioka, Inge Lues

Sci Rep· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice.
Helen Crehan, Bin Liu, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Kevin X Le, Inge Lues

Alzheimers Res Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Inge Lues

Alzheimers Res Ther· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.
Stephan Schilling, Jens-Ulrich Rahfeld, Inge Lues, Cynthia A Lemere

Molecules· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
Maike Hartlage-Rübsamen, Alexandra Bluhm, Anke Piechotta, Miriam Linnert, Jens-Ulrich Rahfeld, Inge Lues

Molecules· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
Torsten Hoffmann, Antje Meyer, Ulrich Heiser, Stephan Kurat, Livia Böhme, Inge Lues

J Pharmacol Exp Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.
Anke Piechotta, Christoph Parthier, Martin Kleinschmidt, Kathrin Gnoth, Thierry Pillot, Inge Lues

J Biol Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients.
Claire Bridel, Torsten Hoffmann, Antje Meyer, Sisi Durieux, Marleen A Koel-Simmelink, Inge Lues

Alzheimers Res Ther· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.
Jeffrey L Frost, Bin Liu, Jens-Ulrich Rahfeld, Martin Kleinschmidt, Brian O'Nuallain, Inge Lues

Neurobiol Aging· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
Inge Lues, Frank Weber, Antje Meyer, Uli Bühring, Torsten Hoffmann

Alzheimers Dement (N Y)· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis